Discover

ADCT
ADC Therapeutics SA
1.14
500 x 1.10
4100 x 1.14
bid
ask
+
0.07
6.54%
2300 @ 06:41 AM
1.14 +0.00 (0.00%)
Ytd-67.71%
1y-57.30%
1.05
day range
1.18
0.78
52 week range
4.98
Open1.05Prev Close1.07Low1.05High1.18Mkt Cap145.00M
Vol1.67MAvg Vol1.84MEPS-0.97P/EN/AForward P/E-1.36
Beta1.60Short Ratio6.98Inst. Own61.60%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0550-d Avg2.62200-d Avg3.621yr Est8.40

ADCT News

ADC Therapeutics Announces New Employee Inducement Grant
prnewswire.com
ADC Therapeutics Announces New Employee Inducement Grant

LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-s

benzinga.com
ADC Therapeutics Completes Enrollment In LOTIS-7 Phase 1b Open-Label Clinical Trial Evaluating ZYNLO

100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamabFull data

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
prnewswire.com
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

benzinga.com
ADC Therapeutics Announces Strategic Reorganization To Focus Resources Behind Key Value-Driving Init

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately

This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday
benzinga.com
This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday

Top Wall Street analysts changed outlook on top names. ADCT downgraded See analysts' views.

ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursday's Pre-Market Session (CORRECTED)
benzinga.com
ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Th

U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.6

Why Is ADC Therapeutics Stock Falling On Friday?
benzinga.com
Why Is ADC Therapeutics Stock Falling On Friday?

Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street ana

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

benzinga.com
RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

RBC Capital analyst Leonid Timashev downgrades ADC Therapeutics (NYSE:ADCT) from Outperform to Se

Why Is ADC Therapeutics Stock Falling Thursday?
benzinga.com
Why Is ADC Therapeutics Stock Falling Thursday?

ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse ev

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why PVH Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why PVH Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket

Shares of PVH fell 21.42% in pre-market trading even after strong Q1. Gainers include CXApp, TaoWeav

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com
ADC Therapeutics Announces Topline Data From Phase 3 LOTIS-5 Confirmatory Trial Evaluating ZYNLONTA

Company to host conference call today at 4:30 p.m. EDTLAUSANNE, Switzerland, June 3, 2026 /PRNewswir

benzinga.com
RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

RBC Capital analyst Leonid Timashev reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and

benzinga.com
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy a

Full Transcript: ADC Therapeutics Q1 2026 Earnings Call
benzinga.com
Full Transcript: ADC Therapeutics Q1 2026 Earnings Call

benzinga.com
ADC Therapeutics Q1 Adj. EPS $(0.13) Beats $(0.21) Estimate, Sales $20.851M Beat $19.240M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.13) per share which beat the analyst c

Earnings Scheduled For May 4, 2026
benzinga.com
Earnings Scheduled For May 4, 2026

benzinga.com
HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Raises Price Target to $8

HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy an

ADC Therapeutics: Q4 Earnings Insights
benzinga.com
ADC Therapeutics: Q4 Earnings Insights

benzinga.com
ADC Therapeutics Q4 Adj. EPS $(0.09) Beats $(0.27) Estimate, Sales $23.058M Beat $21.390M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.09) per share which beat the analyst c

Earnings Scheduled For March 10, 2026
benzinga.com
Earnings Scheduled For March 10, 2026

What to Expect from ADC Therapeutics's Earnings
benzinga.com
What to Expect from ADC Therapeutics's Earnings

benzinga.com
ADC Therapeutics Cuts Change-of-Control Fee on ZYNLONTA Deal in New Royalty Agreement, Lowers Potent

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibo

benzinga.com
ADC Therapeutics Reports Q4, 2025 Preliminary ZYNLONTA Net Product Revenue Of ~$22M, ~$73M, Respecti

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antib

Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
benzinga.com
Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why Is ADC Therapeutics Plunging Today
benzinga.com
Why Is ADC Therapeutics Plunging Today

Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data

Crude Oil Gains 1%; Macy's Reports Strong Q3 Results
benzinga.com
Crude Oil Gains 1%; Macy's Reports Strong Q3 Results

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com
ADC Therapeutics Announces Updated Data From LOTIS-7 Phase 1b Open-Label Clinical Trial Evaluating S

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across th

benzinga.com
ADC Therapeutics Q3 Adj. EPS $(0.19) Beats $(0.36) Estimate, Sales $16.427M Miss $17.077M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.19) per share which beat the analyst c

Earnings Scheduled For November 10, 2025
benzinga.com
Earnings Scheduled For November 10, 2025

benzinga.com
Earnings Preview For ADC Therapeutics

benzinga.com
HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $7

HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy an

benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

Top 5 Biotech Stocks With Strong Momentum
benzinga.com
Top 5 Biotech Stocks With Strong Momentum

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid r

benzinga.com
Guggenheim Reiterates Buy on ADC Therapeutics, Maintains $10 Price Target

Guggenheim analyst Michael Schmidt reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintai

benzinga.com
ADC Therapeutics Q2 Adj. EPS $(0.25) Beats $(0.39) Estimate, Sales $18.839M Beat $17.776M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.25) per share which beat the analyst c

benzinga.com
Earnings Scheduled For August 12, 2025

benzinga.com
Preview: ADC Therapeutics's Earnings

benzinga.com
RBC Capital Maintains Outperform on ADC Therapeutics, Lowers Price Target to $5

RBC Capital analyst Leonid Timashev maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and

benzinga.com
ADC Therapeutics To Present Updated Data From Phase 2 Multicenter IIT Of ZYNLONTA To Treat r/r MZL,

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) o

benzinga.com
Earnings Scheduled For May 14, 2025

benzinga.com
Earnings Scheduled For March 27, 2025

benzinga.com
Earnings Scheduled For March 13, 2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte

benzinga.com
Earnings Scheduled For November 7, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During the session on Thursday, 461 stocks hit new 52-week lows.